Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Summary by The Motley Fool
Key PointsAmgen provides a stable, diversified revenue base of nearly $36.7 billion with significant net income.Iovance Biotherapeutics offers high growth potential through its innovative cell therapies for advanced cancers.Should investors prioritize the reliability of a pharmaceutical giant or the high-reward nature of a biotechnology innovator?10 stocks we like better than Amgen › Does the established stability of a pharmaceutical giant outwe…

1 Articles

The Motley FoolThe Motley Fool
Lean Left

Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Key PointsAmgen provides a stable, diversified revenue base of nearly $36.7 billion with significant net income.Iovance Biotherapeutics offers high growth potential through its innovative cell therapies for advanced cancers.Should investors prioritize the reliability of a pharmaceutical giant or the high-reward nature of a biotechnology innovator?10 stocks we like better than Amgen › Does the established stability of a pharmaceutical giant outwe…

·Alexandria, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Left
100% Left

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

The Motley Fool broke the news in Alexandria, United States on Tuesday, June 23, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Amgen icon

Amgen

Thousand Oaks icon

Thousand Oaks

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal